Aptevo Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 14, 2025
APVO$1.13-8.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(in thousands, except share and per share amounts)
| For the Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating expenses: | ||
| Research and development | $(14,378) | $(17,107) |
| General and administrative | (10,224) | (11,771) |
| Loss from operations | (24,602) | (28,878) |
| Other income: | ||
| Other income from continuing operations, net | 472 | 578 |
| Gain related to sale of non-financial asset | — | 9,650 |
| Net loss from continuing operations | $(24,130) | $(18,650) |
| Discontinued operations: | ||
| Income from discontinued operations | $— | $1,239 |
| Net loss | $(24,130) | $(17,411) |
| Basic and diluted net loss per share from continuing operations: | ||
| Basic | $(87.38) | $(2,481.70) |
| Diluted | $(87.38) | $(2,481.70) |
| Basic and diluted net loss per share: | ||
| Basic | $(87.38) | $(2,316.83) |
| Diluted | $(87.38) | $(2,316.83) |
| Shares used in calculation: | ||
| Basic | 276,137 | 7,515 |
| Diluted | 276,137 | 7,515 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.